ARBs (Angiotensin Receptor Blockers): A Cardiologist's Guide to How They Work, the Drugs, and the Trials

Angiotensin receptor blockers (ARBs) generate more questions in my Encinitas practice than almost any other drug class. The names alone are a mouthful, losartan, valsartan, olmesartan, telmisartan, irbesartan, candesartan, azilsartan, and patients want to know what they actually do, why I picked a specific one, and whether the differences between agents matter. This guide is the honest explanation of how ARBs work, where they sit in modern cardiovascular care, how they compare to ACE inhibitors, and what I monitor when I prescribe them.

What System Are ARBs Designed to Block?

ARBs block the AT1 receptor for angiotensin II. The renin-angiotensin-aldosterone system (RAAS) is an ancient hormone circuit that regulates blood pressure and salt/water balance. Angiotensin II is the workhorse of the system: it constricts blood vessels, signals the kidneys to retain sodium and water, drives thirst, and stimulates cardiac and vascular remodeling. ARBs block the bad-actor receptor and leave the AT2 receptor (which has more protective effects) intact.

The cascade runs in steps. When blood pressure drops or the kidneys sense low sodium, the kidneys release renin. Renin cleaves angiotensinogen to angiotensin I. Angiotensin-converting enzyme (ACE) converts angiotensin I to angiotensin II. Angiotensin II then acts on two receptors:

• AT1 receptor: vasoconstriction, sodium retention, aldosterone release, sympathetic activation, cardiac hypertrophy, vascular smooth muscle proliferation, fibrosis. The bad actor.
• AT2 receptor: vasodilation, anti-inflammatory effects, anti-proliferative effects. The protective one.

ARBs selectively block AT1. ACE inhibitors work earlier in the pathway by blocking ACE, which reduces angiotensin II production (but does not block AT1 directly). Both classes shut down most of the bad-actor effects. The key practical differences come from how each class handles bradykinin, a separate molecule that ACE inhibitors cause to accumulate.

In modern life, this hormone system is rarely needed in the way it evolved to be. The salt and water conservation that kept our ancestors alive during dehydration and blood loss is no longer the dominant problem. For most patients with hypertension, heart failure, or kidney disease, the RAAS is on overdrive, raising blood pressure too high, driving cardiac remodeling, and damaging the kidneys.

What Does ARB Blockade Actually Do?

Blocking the AT1 receptor lowers blood pressure (through vasodilation and natriuresis), reduces afterload on the failing heart, allows reverse remodeling of left ventricular hypertrophy, and protects the kidneys by relaxing the efferent arteriole and reducing intraglomerular pressure. The result is a long list of clinical uses: hypertension, heart failure, diabetic and non-diabetic kidney disease, post-MI care, AF prevention, and aortic protection in Marfan syndrome and bicuspid aortic valve.

In blood vessels, AT1 blockade relaxes the smooth muscle in vessel walls, dilating them and lowering systemic vascular resistance. Blood pressure falls.

In the adrenal glands, AT1 blockade reduces aldosterone release. Less aldosterone means less sodium reabsorption in the distal nephron, which lowers blood pressure further. It also means less potassium excretion, which is the basis for the mild hyperkalemia risk on ARBs.

In the heart, sustained AT1 blockade reduces the trophic signal driving left ventricular hypertrophy. Over months to years, a thickened ventricle (a common consequence of long-standing hypertension or aortic stenosis) can remodel toward normal. In HFrEF, the reduced afterload allows better forward stroke volume, and the reduced neurohormonal drive slows the deterioration that defines untreated heart failure.

In the kidneys, AT1 blockade relaxes the efferent arteriole specifically. This drops the pressure inside the glomerular capillary bed and protects the filtration apparatus from the slow damage of long-standing hypertension and diabetes. The effect is the basis for the renoprotective indications: diabetic nephropathy (IDNT and IRMA-2 trials with irbesartan), non-diabetic CKD, and post-transplant care.

What Are the Main Clinical Uses?

ARBs are first-line for hypertension, foundational therapy for HFrEF (typically as sacubitril-valsartan), kidney-protective in diabetic and non-diabetic CKD, post-MI alternatives to ACE inhibitors, used for AF recurrence prevention in patients with hypertension and atrial enlargement, and used to slow aortic dilation in Marfan syndrome and bicuspid aortic valve disease.

ARB Indications by Clinical Context

The ARB sits foundational in modern multi-drug regimens for cardiovascular and kidney protection. In a typical HFrEF patient I see in clinic, the medication list includes an ARB (often as sacubitril-valsartan), a beta-blocker, a mineralocorticoid receptor antagonist, an SGLT2 inhibitor, and increasingly a GLP-1 receptor agonist if the patient also has obesity or diabetes. Each layer addresses a different pathway, and the ARB is the foundation the rest of the regimen builds on.

How Do ARBs Compare to ACE Inhibitors?

For hard endpoints (cardiovascular death, MI, stroke), ARBs and ACE inhibitors are clinically equivalent. The ONTARGET trial (25,620 patients) showed nearly identical event rates for telmisartan vs ramipril (16.7% vs 16.5%, HR 1.01). The practical difference is tolerability: ARBs cause less cough (1.1% vs 4.2%) and less angioedema (0.1% vs 0.3%) in head-to-head data.

ONTARGET (NEJM 2008) was the definitive head-to-head trial. It enrolled 25,620 high-risk vascular patients and randomized them to ramipril (an ACE inhibitor), telmisartan (an ARB), or both. Over a median 4.7 years, the cardiovascular event rates were nearly identical between ramipril and telmisartan. The combination arm did worse, more low blood pressure, more kidney injury, more hyperkalemia, with no improvement in hard outcomes. The trial established two things at once. ARBs and ACE inhibitors are equivalent for hard endpoints, and the two classes should not be combined in the same patient.

The choice between ARB and ACE inhibitor for a given patient comes down to tolerability and cost. ACE inhibitors cause a dry cough in 4 to 20% of patients (depending on how strictly the definition is applied), driven by bradykinin accumulation in the airways. ARBs do not affect bradykinin and so rarely cause cough. Angioedema is rarer with both classes but is more dangerous and is the reason a patient with a prior ACE inhibitor angioedema is usually switched to an ARB with caution (3.5% cross-reactivity) or to a different class entirely.

Most of my patients can take either class. I default to whichever I think will be best tolerated. If a patient develops a persistent dry cough on an ACE inhibitor, I switch them to an ARB without losing any hard-outcome benefit.

What Are the Differences Among the ARBs?

Within the class, the agents are more similar than different. The differences worth knowing: losartan is the oldest and cheapest but has the shortest half-life. Valsartan has the deepest heart failure evidence and is the ARB component of sacubitril-valsartan. Telmisartan has the longest half-life. Olmesartan and azilsartan are the most potent on a mg-for-mg basis. Candesartan has the strongest HFpEF evidence. Irbesartan has the deepest diabetic nephropathy evidence.

ARB Comparison

For straight hypertension in a patient without specific comorbidity, any ARB will work and the choice usually comes down to cost (losartan is the cheapest) and patient preference. For HFrEF, I default to valsartan as sacubitril-valsartan because of the PARADIGM-HF mortality data. For diabetic nephropathy, irbesartan or losartan are the agents with the deepest evidence. For LVH regression in hypertensive patients, losartan has the LIFE trial data showing it outperformed atenolol on stroke prevention.

What Should Be Monitored on an ARB?

Check serum creatinine and potassium within 1-2 weeks of starting or increasing the dose, and periodically thereafter. A creatinine rise up to 30% is expected and acceptable. Potassium rises modestly (often 0.3 to 0.5 mEq/L), more in CKD or with concomitant spironolactone or potassium supplements. Larger creatinine jumps suggest dehydration, narrowed renal arteries, or another drug interfering with renal blood flow.

The creatinine rise on an ARB has a specific mechanism: AT1 blockade relaxes the efferent arteriole, which drops the pressure inside the glomerulus. The drop in filtration pressure produces a small rise in serum creatinine. This is expected and is a sign the drug is working at the kidney level. A 30% rise is acceptable. A larger jump (or a creatinine that keeps climbing over weeks) warrants investigation for renal artery stenosis, volume depletion, NSAID co-administration, or contrast nephropathy.

Potassium monitoring matters because the suppression of aldosterone reduces potassium excretion. In a patient with normal kidney function and no potassium-sparing co-medications, the rise is small. In a patient on spironolactone, with advanced CKD, or taking a potassium supplement, the rise can reach dangerous levels. I check labs within 2 weeks of any dose escalation in higher-risk patients.

For blood pressure itself, the 2017 ACC/AHA hypertension guideline target is below 130/80 mmHg in most adults. Home blood pressure monitoring averaged over 5 to 7 days is more reliable than a single office reading for titration decisions. When the ARB alone does not get the patient to target, I add a calcium channel blocker (amlodipine) or a thiazide diuretic (chlorthalidone or indapamide) per the ACCOMPLISH and broader hypertension trial framework, before reaching for additional agents.

When Are ARBs the Wrong Choice?

Avoid ARBs in pregnancy (severe fetal harm including kidney failure and oligohydramnios), bilateral renal artery stenosis (sudden kidney failure risk), prior ACE inhibitor angioedema (3.5% cross-reactivity), and severe pre-existing hyperkalemia (potassium > 5.5 mEq/L). Use caution in single kidney with stenosis, severe volume depletion, and active worsening of kidney function for any reason.

Pregnancy is an absolute contraindication. ARBs cause fetal renal failure, low amniotic fluid, lung hypoplasia, and skull hypoplasia when given in the second or third trimester. The first trimester signal is smaller but real. Women of reproductive age on an ARB need reliable contraception, and any pregnancy on an ARB requires immediate switch to a pregnancy-safe alternative (methyldopa, labetalol, nifedipine) and maternal-fetal medicine consultation.

Bilateral renal artery stenosis (or stenosis in a single functioning kidney) is the most dangerous renovascular contraindication. The kidneys depend on angiotensin II’s vasoconstrictive effect on the efferent arteriole to maintain adequate filtration pressure when renal blood flow is restricted by the stenosis. Blocking it can produce sudden acute kidney injury. The clinical clue is a patient with severe difficult-to-control hypertension whose creatinine rises dramatically after starting an ARB or ACE inhibitor; that is the time to image the renal arteries.

Prior ACE inhibitor angioedema is a relative contraindication. The cross-reactivity rate to ARBs is about 3.5%. For a patient with mild ACE inhibitor angioedema and a strong indication for RAAS blockade, an ARB can be tried cautiously with patient counseling. For a patient with severe airway angioedema on an ACE inhibitor, a different class entirely is safer.

Severe baseline hyperkalemia (K > 5.5 mEq/L) should be corrected before starting an ARB. Patiromer or sodium zirconium cyclosilicate are options for chronic management of hyperkalemia in patients who need ARB therapy for HFrEF or kidney protection but cannot tolerate the potassium rise alone.

How Do ARBs Fit Into Modern Cardiovascular Care?

ARBs are foundational, not stand-alone. In modern HFrEF care, the ARB sits underneath sacubitril-valsartan, a beta-blocker, a mineralocorticoid receptor antagonist, and an SGLT2 inhibitor. In CKD with diabetes, the ARB sits underneath an SGLT2 inhibitor, finerenone (FIDELIO-DKD, FIGARO-DKD), and often a GLP-1 receptor agonist. The layering is what produces the modern survival and event-free benefit.

Twenty years ago, the debate around ARBs was whether they were as good as ACE inhibitors. That question is settled. The more interesting story is what gets layered on top.

Sacubitril-valsartan combines an ARB (valsartan) with a neprilysin inhibitor (sacubitril) that preserves endogenous natriuretic peptides. In the PARADIGM-HF trial, sacubitril-valsartan reduced cardiovascular death and heart failure hospitalization by 20% compared with enalapril. It is now first-line over ACE inhibitor monotherapy in HFrEF.

SGLT2 inhibitors (empagliflozin, dapagliflozin) layered on top of background ARB therapy reduce heart failure events and slow CKD progression. DAPA-HF, EMPEROR-Reduced, EMPEROR-Preserved, DAPA-CKD, and EMPA-KIDNEY collectively established this layered approach as standard.

Finerenone, a selective mineralocorticoid receptor antagonist, layers on top of ARBs in diabetic kidney disease for additional cardiorenal benefit. FIDELIO-DKD and FIGARO-DKD demonstrated reductions in CKD progression and cardiovascular events.

GLP-1 receptor agonists layered on top in patients with obesity, diabetes, or both add cardiovascular and kidney benefit (FLOW, SELECT, SUMMIT).

A patient of mine on an ARB plus an SGLT2 inhibitor plus a GLP-1 receptor agonist plus a statin is on the modern foundation of cardiometabolic protection. Each drug targets a different pathway. Each is proven. Together they reduce cardiovascular events, kidney disease progression, and mortality far more than any single agent could.

What Should You Do If You Are On an ARB?

Take it at the same time every day. Call your cardiologist if you develop unexplained cough or angioedema-like swelling (more likely from an ACE inhibitor than an ARB, but worth knowing), lightheadedness, muscle weakness that might suggest high potassium, or pregnancy/planned pregnancy. Do not stop the drug abruptly without consultation, especially if you have HFrEF or CKD, where rebound can be substantial.

The most common reasons patients stop an ARB on their own:

• Cost. Generic ARBs (losartan, valsartan, irbesartan) are widely available and inexpensive. If cost is an issue, ask about a switch to a generic option.
• Lightheadedness. Often related to initial dose titration or dehydration. Manageable with dose timing changes (evening dosing), dose reduction, or attention to fluid status.
• Lab abnormalities found by another provider. A creatinine rise of up to 30% is expected and acceptable. A larger jump is worth a workup, not a knee-jerk discontinuation.
• Fear from old recall stories. The 2018-2019 generic valsartan, losartan, and irbesartan recalls were caused by an NDMA contaminant in products from specific manufacturers. The FDA has worked with manufacturers to clean up the impurities. Generic ARBs in US pharmacies today have been re-approved and are safe.

If you are pregnant or planning a pregnancy, tell your cardiologist immediately. The switch to a pregnancy-safe alternative needs to happen before conception when possible, not after a positive test.

ARBs: The Bottom Line

ARBs are one of the most studied, safest, and most useful classes of cardiovascular drugs in existence. They are first-line for hypertension, foundational for HFrEF (typically as sacubitril-valsartan), kidney-protective in diabetic and non-diabetic CKD, and have a defined role in post-MI care, AF prevention, and aortic protection in Marfan and bicuspid valve disease.

The trial evidence is overwhelming, the safety profile is excellent, the cost (with generics) is low, and the tolerability is better than ACE inhibitors for most patients. If your cardiologist has prescribed an ARB, you are on one of the most evidence-based cardiovascular therapies available. Take it consistently, attend the follow-up lab checks, and call about any new symptoms that might warrant a dose adjustment or class switch.

Frequently Asked Questions About ARBs

What is the difference between an ARB and an ACE inhibitor?

ACE inhibitors block the production of angiotensin II. ARBs block angiotensin II from acting at its receptor once it is produced. The end result is similar lowering of blood pressure and similar protection for the heart and kidneys. The main practical difference is tolerability: ACE inhibitors cause cough in 4 to 20% of patients (bradykinin-mediated) and ARBs essentially do not. (For a deeper comparison, see ARB vs ACE inhibitor.)

Can I drink alcohol on an ARB?

Moderate alcohol (no more than 1 drink per day for women, 2 for men) is generally fine. Heavy drinking can drop blood pressure too far when combined with an ARB and raises blood pressure on its own when chronic. Discuss your alcohol intake honestly with your cardiologist.

Will I need to be on this for life?

For most patients, yes. Hypertension, HFrEF, and CKD are chronic conditions. Some patients with mild hypertension can come off after real weight loss, sodium reduction, and improvement in other drivers. The decision is reassessed at every visit.

Are generic ARBs as good as brand-name versions?

Yes. Generic losartan, valsartan, olmesartan, irbesartan, and most others contain the same active ingredient at the same dose with the same effect as the brand. Cost should not be a barrier to taking your medication.

I had a recall scare with my valsartan a few years back. Is the generic safe now?

Yes. The 2018-2019 recalls were caused by an NDMA contaminant in some generic valsartan, losartan, and irbesartan products from specific manufacturers. The FDA worked with manufacturers to clean up the impurities. Generic ARBs sold in US pharmacies today have been re-approved and are safe.

Can I take an ARB during pregnancy?

No. ARBs cause severe fetal harm including renal failure, oligohydramnios, lung hypoplasia, and skull hypoplasia. Women of reproductive age on an ARB need reliable contraception. Any pregnancy or planned pregnancy requires immediate switch to a pregnancy-safe agent (methyldopa, labetalol, nifedipine).

Can I take an ARB with an SGLT2 inhibitor and a GLP-1?

Yes, and for many patients with diabetes, kidney disease, or heart failure that combination is exactly the right plan. Each drug protects the heart and kidneys through a different pathway and they add to each other rather than compete.

Why did my creatinine go up after starting an ARB?

A rise of up to 30% is expected. ARBs relax the efferent arteriole in the kidney, which lowers intraglomerular pressure and slightly drops the filtration rate. This is a sign the drug is working at the kidney level. A larger jump warrants investigation for renal artery stenosis, dehydration, NSAID co-administration, or contrast exposure.

References

1. ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. New England Journal of Medicine. 2008;358(15):1547-1559.

2. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure (PARADIGM-HF). New England Journal of Medicine. 2014;371(11):993-1004.

3. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular Morbidity and Mortality in the Losartan Intervention For Endpoint Reduction in Hypertension Study (LIFE). Lancet. 2002;359(9311):995-1003.

4. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes (IDNT). New England Journal of Medicine. 2001;345(12):851-860.

5. Pfeffer MA, Swedberg K, Granger CB, et al. Effects of Candesartan on Mortality and Morbidity in Patients with Chronic Heart Failure (CHARM-Overall). Lancet. 2003;362(9386):759-766.

6. Cohn JN, Tognoni G. A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure (Val-HeFT). New England Journal of Medicine. 2001;345(23):1667-1675.

7. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients (ACCOMPLISH). New England Journal of Medicine. 2008;359(23):2417-2428.

8. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults. Hypertension. 2018;71(6):e13-e115.

9. Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes (FIDELIO-DKD). New England Journal of Medicine. 2020;383(23):2219-2229.

10. Pfeffer MA, McMurray JJV, Velazquez EJ, et al. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both (VALIANT). New England Journal of Medicine. 2003;349(20):1893-1906.

11. Parving HH, Lehnert H, Bröchner-Mortensen J, et al. The Effect of Irbesartan on the Development of Diabetic Nephropathy in Patients with Type 2 Diabetes (IRMA-2). New England Journal of Medicine. 2001;345(12):870-878.

12. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy (RENAAL). New England Journal of Medicine. 2001;345(12):861-869.